<DOC>
	<DOCNO>NCT00229099</DOCNO>
	<brief_summary>The purpose study establish equivalence GerEpo standard treatment Eprex® treatment period 12 week patient Hemodialysis respect hemoglobin response establish longer-term safety profile GerEpo , special regard occurrence Pure Red Cell Aplasia ( PRCA ) immunogenicity relate adverse event</brief_summary>
	<brief_title>Efficacy Safety Study GerEPO</brief_title>
	<detailed_description>270 patient Hemodialysis 25 participate site meet inclusion/exclusion criterion enrol trial . At end comparative trial , subject either arm study may opt enter long term cohort study design establish longer-term safety profile GerEpo , special regard occurrence Pure Red Cell Aplasia ( PRCA ) immunogenicity relate adverse event . This second part study also open subject give write informed consent , ESRF CRF relate anemia accord current guideline treat Epoetin . Subjects need include first part study . All patient shall treat GerEpo thereafter observe least 1 year actively monitor occurrence PRCA immunogenicity related adverse event . The cohort study shall continue least 10,000 patient-years observation accrue study database .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>1 . Written inform consent obtain . 2 . Patients age 18 70 year . 3 . Patients medically stable hemodialysis minimum 3 month . 4 . Patients Eprex® treatment CRF relate anemia maintain Hb level 9 g/dL ( 90g/L ) stable dose ( change dose ) Epoetin within 6 week precede screen phase study . 5 . Patients serum ferritin level great 100μg/L and/or transferrin saturation least 20 % within 3 month precede screen phase study . 1 . Pregnant nursing woman , woman childbearing potential without effective method birth control . Effective birth control method oral contraception , Norplant , surgical sterilization , IUD diaphragms conjunction spermicidal foam condom male partner . 2 . Participation drug trial patient receive Epoetin investigational drug within 30 day precede screen phase study . 3 . Those person directly involve conduct study . 4 . Poorly control hypertension diastolic blood pressure persistently great 110 mmHg baseline observation . 5 . History seizure disorder . 6 . Active acute chronic infection inflammatory disease . 7 . Any illness require hospitalization within last one month . 8 . Had blood transfusion within last three month . 9 . Significant hematologic abnormality ( Evidence hemolysis laboratory test , unexplained acquire microcytosis , thrombocytosis ( &gt; 500,000/mm3 ) ) 10 . Severe hyperparathyroidism 11 . Diagnosed malignant tumor residual tumor anticancer therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2005</verification_date>
</DOC>